Tarsus Pharmaceuticals Inc’s recent filing unveils that its Officer Azamian Bobak R. acquired Company’s shares for reported $0.3 million on Aug 11 ’25. In the deal valued at $50.00 per share,6,000 shares were bought.
Then, Farrow Jeffrey S sold 13,608 shares, generating $550,035 in total proceeds. Upon selling the shares at $40.42, the insider now owns 36,704 shares.
Before that, Farrow Jeffrey S bought 13,608 shares. Tarsus Pharmaceuticals Inc shares valued at $550,088 were divested by the Officer at a price of $40.42 per share.
Goldman began covering TARS with “Neutral” recommendation on November 20, 2023. William Blair started covering the stock on July 18, 2023. It rated TARS as “an Outperform”.
Price Performance Review of TARS
On Monday, Tarsus Pharmaceuticals Inc [NASDAQ:TARS] saw its stock jump 4.64% to $50.07. Over the last five days, the stock has gained 19.47%. Tarsus Pharmaceuticals Inc shares have risen nearly 120.67% since the year began. Nevertheless, the stocks have fallen -9.57% over the past one year. While a 52-week high of $57.28 was reached on 02/05/25, a 52-week low of $24.95 was recorded on 08/01/25.
Levels Of Support And Resistance For TARS Stock
The 24-hour chart illustrates a support level at 48.08, which if violated will result in even more drops to 46.10. On the upside, there is a resistance level at 51.57. A further resistance level may holdings at 53.08.
How much short interest is there in Tarsus Pharmaceuticals Inc?
A steep rise in short interest was recorded in Tarsus Pharmaceuticals Inc stocks on 2025-07-15, growing by 96830.0 shares to a total of 8.21 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 8.11 million shares. There was a rise of 1.18%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on May 18, 2023 when Guggenheim began covering the stock and recommended ‘”a Buy”‘ rating.
